The exact incidence of LS is hard to determine because many cases are asymptomatic, undiagnosed, or misdiagnosed. For females, estimates of 0.1 to 3% have been reported in certain populations, and for males, estimated prevalence is around 0.07%. Approximately 6% of LS cases involve areas of the body outside of the genital region. LS can affect all ethnicities, although it is reported most often in Caucasian populations.

A definitive cause of lichen sclerosus is not established. It is likely multifactorial with autoimmune mechanisms playing a role. Autoimmune thyroid disease is seen in about 12-16% of patients, and associations with vitiligo (loss of skin color in patches), alopecia areata (spot baldness), pernicious anemia (impaired Vitamin B12 absorption), type 1 diabetes, and autoantibodies to extracellular matrix protein 1 (ECM1) and other cell membrane components are found in many patients.  A genetic predisposition is likely as 10-12% of affected individuals have a positive family history, and twin case studies support a hereditary link. External triggers such as local skin trauma, injury, friction, or previous infections may provoke the onset of the condition in genetically predisposed individuals. Hormonal influences may play a role in contributing to LS around menopause and before puberty.

Clinical presentation of LS ranges from entirely asymptomatic to severely debilitating. Symptoms primarily affect the vulva, anus or penis, and may include the following:

• Visible skin changes: Porcelain-white papules or plaques that eventually coalesce into wrinkled, thin patches resembling cigarette paper.

• Pruritus (Itching): Often severe and characteristically worse at night, frequently disrupting sleep.

• Pain and Discomfort: Scratching or friction can easily lead to tearing, bleeding, blisters, and bruising.

• Functional impairment: Women may experience painful sexual intercourse and tearing during bowel movements. In men, it commonly causes phimosis (inability to retract the foreskin), painful erections and disrupted urinary flow.

Extragenital symptoms may include white, shiny, slightly depressed papules or plaques on the trunk, breasts, thighs, wrists or neck; often asymptomatic or mildly itchy. In children, itching, soreness, bleeding, constipation and urinary problems may appear;  bruises can be mistaken for trauma or abuse.

Diagnosis is typically made visually by a healthcare provider based on the clinical appearance of the characteristic skin changes and patient history. A tissue biopsy is often performed if lesions fail to respond to first-line topical treatments and to rule out cancer. Examination for associated autoimmune disease may be appropriate when clinically indicated.

Because LS is a chronic condition, treatment aims to induce remission, relieve debilitating symptoms, prevent progressive anatomical scarring, and reduce the long-term risk of malignant transformation.

• Topical Corticosteroids: The gold standard, first-line treatment is the application of ultra-potent topical steroid ointments, such as clobetasol.

• Topical Calcineurin Inhibitors: Immunosuppressants like tacrolimus ointment can be used to inhibit the enzyme calcineurin involved in immune cell activation.

• Emollients and Barrier Care: Liberal use of unscented moisturizers, such as petroleum jelly, helps protect the compromised skin barrier, retain moisture, and reduce friction;  wear loose-fitting clothing;  avoid scratching.

• Surgery: In males, circumcision is frequently recommended and can sometimes be fully curative for isolated foreskin involvement. In females, surgery is strictly reserved for releasing severe adhesions or strictures that impede urination or sexual function, typically combined with hormone or steroid therapy to prevent recurrence.

Lichen sclerosus is generally a lifelong, chronic, relapsing condition that requires ongoing maintenance therapy and diligent surveillance. Without rigorous intervention, the condition can lead to progressive scarring and permanent structural changes. While LS itself is not cancerous, it is associated with an elevated lifetime risk of developing squamous cell carcinoma (SCC) of the vulva or penis, estimated between 3-5%. For this reason, continuous clinical follow-up is strongly recommended. Extragenital LS often has a milder course and may resolve spontaneously.

1. Kirtschig G. (2016). “Lichen Sclerosus-Presentation, Diagnosis and Management.” Dtsch Arztebl Int. 113(19):337-43. doi: 10.3238/arztebl.2016.0337. PMID: 27232363; PMCID: PMC4904529.

2. Fergus KB, Lee AW, Baradaran N, Cohen AJ, Stohr BA, Erickson BA, Mmonu NA, Breyer BN. (2020). “Pathophysiology, Clinical Manifestations, and Treatment of Lichen Sclerosus: A Systematic Review”. Urology. 135:11-19. doi: 10.1016/j.urology.2019.09.034. Epub 2019 Oct 9. PMID: 31605681.

3. National organization for rare disorders (NORD):  Lichen sclerosis.

4. Cleveland Clinic:  Lichen sclerosis.